香菇多糖
 | |
| 臨床資料 | |
|---|---|
| 其他名稱 | (2S,3R,4S,5S,6R)-2-[(2S,3R,4S,5R,6R)-2-[(2S,3R,4S,5R,6R)-2-[(2R,3R,4S,5R,6S)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3R,4S,5R,6R)-2,3,5-trihydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-4-yl]oxyoxan-4-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,5-dihydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol |
| AHFS/Drugs.com | 国际药品名称 |
| ATC碼 | |
| 识别信息 | |
| |
| CAS号 | 37339-90-5  |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| CompTox Dashboard (EPA) | |
| 化学信息 | |
| 化学式 | C42H72O36 |
| 摩尔质量 | 1152.99948 g/mol |
香菇多糖[1]（英語：Lentinan）是从香菇（Lentinula edodes）子实体中分离出来的一种多糖。以β-1,3-葡聚糖为主，在6号位碳原子上有支链。通过静脉注射，有免疫激活和抗肿瘤活性，特別是胃癌。[2]
化学
[编辑]香菇多糖是一种β-1,3葡聚糖，在β-1,6（6号位碳原子）有支链结构。其分子量为500,000道尔顿（Da），比旋光度为+14-22° (NaOH)。
研究
[编辑]临床前研究
[编辑]体外实验表明，香菇多糖可刺激人类细胞系U937产生白细胞。[3] 人们认为口服香菇多糖对人体无活性，因此通常采用静脉注射给药。一项体内研究表明，香菇多糖口服可能对小鼠有效。[4]
人体临床试验
[编辑]在日本，香菇多糖已成为少数癌症患者临床研究的对象；[5][6][7][8][9][10][11][12] 然而，缺乏疗效证据。[13][14]
不良反应
[编辑]参阅
[编辑]参考文献
[编辑]- ^ ? （中文（简体））.[永久失效連結]
- ^ 存档副本. [2015-02-02]. （原始内容存档于2012-03-21）. （页面存档备份，存于互联网档案馆）
- ^ Sia GM, Candlish JK. Effects of shiitake (Lentinus edodes) extract on human neutrophils and the U937 monocytic cell line. Phytotherapy Research. March 1999, 13 (2): 133–137. PMID 10190187. doi:10.1002/(SICI)1099-1573(199903)13:2<133::AID-PTR398>3.0.CO;2-O
.
- ^ Ng ML, Yap AT. Inhibition of human colon carcinoma development by lentinan from shiitake mushrooms (Lentinus edodes). Journal of Alternative and Complementary Medicine. October 2002, 8 (5): 581–589. PMID 12470439. doi:10.1089/107555302320825093.
- ^ Yang P, Liang M, Zhang Y, Shen B. Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC. Advances in Therapy. August 2008, 25 (8): 787–794. PMID 18670743. S2CID 33140754. doi:10.1007/s12325-008-0079-x .
- ^ Nimura H, Mitsumori N, Takahashi N, Kashimura H, Takayama S, Kashiwagi H, Yanaga K. [S-1 combined with lentinan in patients with unresectable or recurrent gastric cancer]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. June 2006,. 33 Suppl 1 (1): 106–109. PMID 16897983 （日语）.
- ^ Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K. A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group. Hepato-Gastroenterology. 1999, 46 (28): 2662–2668. PMID 10522061.
- ^ Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J. Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer. Anticancer Research. July 2009, 29 (7): 2739–2745. PMID 19596954.
- ^ Hazama S, Watanabe S, Ohashi M, Yagi M, Suzuki M, Matsuda K, et al. Efficacy of orally administered superfine dispersed lentinan (beta-1,3-glucan) for the treatment of advanced colorectal cancer. Anticancer Research. July 2009, 29 (7): 2611–2617. PMID 19596936.
- ^ Kataoka H, Shimura T, Mizoshita T, Kubota E, Mori Y, Mizushima T, et al. Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life. Hepato-Gastroenterology. 2009, 56 (90): 547–550. PMID 19579640.
- ^ Isoda N, Eguchi Y, Nukaya H, Hosho K, Suga Y, Suga T, et al. Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma. Hepato-Gastroenterology. 2009, 56 (90): 437–441. PMID 19579616.
- ^ Shimizu K, Watanabe S, Watanabe S, Matsuda K, Suga T, Nakazawa S, Shiratori K. Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer. Hepato-Gastroenterology. 2009, 56 (89): 240–244. PMID 19453066.
- ^ Lentinan. WebMD. [June 10, 2017].
- ^ Lentinan. Memorial Sloan Kettering Cancer Center. [June 10, 2017].
- ^ Nakamura T. Shiitake (Lentinus edodes) dermatitis. Contact Dermatitis. August 1992, 27 (2): 65–70. PMID 1395630. S2CID 7320474. doi:10.1111/j.1600-0536.1992.tb05211.x.
